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ABSTRACT
Brazil, the world’s top consumer of agricultural pesticides, adopts a unique hazard-
based cut-off approach to pesticide registration. Cut-off criteria for mutagenicity, 
carcinogenicity, teratogenicity, hormonal disturbances and damage to reproductive 
organs were introduced by the Pesticide Law enacted in 1989. As far as health is 
concerned, law enforcement is additionally regulated by rules issued by the federal 
health authority (National Agency for Health Surveillance – ANVISA). Contrasting to 
the European Union’s hazard-based cut-off criteria for pesticides, Brazilian rules do 
not make an exception for “negligible” exposures. Moreover, Brazilian regulations 
have shortcomings (e.g. no reference to relevance of Mode of Action to humans) that 
make cut-off criteria diffi cult to be put into effect. The defi ciencies of regulations and 
diffi culties to consistently apply the hazard-based cut-off criteria are appraised in this 
article. Adoption of a risk assessment approach or cut-off criteria based on classifi cation 
into the Globally Harmonized System’s hazard categories 1A and 1B is suggested.
KEYWORDS: Risk assessment; Hormonal disturbances; Teratogenicity; Carcinogenicity; 
Mutagenicity
RESUMO
O Brasil, líder mundial do consumo de agro-químicos, adota uma singular abordagem para 
registro de agrotóxicos que é baseada em critérios de exclusão quanto à periculosidade. 
Critérios de exclusão para mutagenicidade, carcinogenicidade, teratogenicidade, 
distúrbios hormonais e dano a órgãos reprodutivos foram introduzidos pela Lei de 
Agrotóxicos promulgada em 1989. Em relação à saúde, a aplicação da lei é também 
regulada por portarias publicadas pela autoridade sanitária federal (Agência Nacional 
de Vigilância Sanitária – ANVISA). Em contraste com os critérios de exclusão baseados 
na periculosidade que a União Européia usa para agrotóxicos, a regulamentação 
brasileira não faz exceção para exposições insignifi cantes. Além disso, a regulamentação 
brasileira apresenta defi ciências (e.g., não faz menção à relevância do modo de ação 
para seres humanos) que tornam difícil a aplicação dos critérios de exclusão. As falhas 
dos regulamentos e as difi culdades para aplicar consistentemente os critérios de 
exclusão baseados na periculosidade são examinados neste artigo. Sugere-se a adoção 
da avaliação de risco ou de critérios de exclusão baseados na classifi cação quanto a 
periculosidade (categorias 1A e 1B) do Sistema Harmonizado Globalmente.
PALAVRAS-CHAVE: Avaliação de risco; Distúrbios hormonais; Teratogenicidade; 
Carcinogenicidade; Mutagenicidade
Critérios de exclusão baseados em perigo adotados no Brasil para registro 
de pesticidas: Uma avalição crítica
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Introduction
The notion that the magnitude of a toxic reaction depends 
on the amount of substance to which someone is exposed - or 
that “the dose makes the poison” - is a cornerstone principle of 
toxicological science. A direct corollary of this principle is the 
idea that there should always be a dose (exposure level) below 
which no toxicity occurs. Both notions are conveyed by the 
famous maxim “All things are poison and nothing is without 
poison; only the dose makes a thing not a poison” (“Alle Dinge 
sind Gift und nichts ist ohne Gift; allein die dosis machts, dass 
ein Ding kein Gift sei.”), enunciated by Paracelsus almost fi ve 
centuries ago1. It should be highlighted that Paracelsus used 
the negative (“..the dose makes a thing not a poison”) instead 
of the affi rmative form (“..the dose makes a thing a poison”) to 
convey his ideas 1,2. Taking a top-down view of dose/exposure-
toxic effect relationships, as modern toxicologists do for risk 
assessment, Paracelsus seemed to be far ahead of his time 2.
To assess the risk of a chemical substance, today’s 
toxicologists use data from animal and human studies to 
identify the hazard and uncover dose/exposure – toxic 
response relationships. The risk assessment process provides a 
rational basis for interventions (including regulatory decisions) 
aimed at protecting the population from health hazards posed 
by thousands of natural and man-made chemicals we have to 
live with in our increasingly technology-driven society 2,3.
Pesticide toxicity, hazard and risk
Although hazard and risk are terms commonly used by 
toxicologists and public health scientists, the distinction 
between them is not always clearly understood by non-experts.
Hazard is a source of potential harm or adverse health 
effect on someone that may or may not occur depending on 
certain conditions. Sometimes, however, the word hazard 
is employed to refer to the harm or adverse health effect 
produced rather than to its source. For instance, although a 
chemical carcinogen is generally considered a hazard, or a 
hazardous agent, its effect – cancer - might be at times called 
a hazard as well.
Risk, on the other hand, is a probabilistic concept. As far 
as toxicity is concerned, risk is the chance or probability that 
a person or animal will experience an adverse health effect if 
exposed (under certain conditions) to a chemical.
Therefore, while hazard is something or a set of 
circumstances that can potentially harm a person’s health, 
risk is the likelihood (or probability) that a person will be 
harmed by a particular hazard. 
The likelihood of developing an illness or getting injured 
after being exposed to a chemical agent depends on the level 
of exposure (actually, the internal dose received) as well as 
on some other factors. For instance, if exposure to a toxic 
substance is negligible, so is the health risk associated with 
it. A less hazardous chemical, on the other side, may pose a 
signifi cant health risk if anticipated levels of exposure in real 
world scenarios are high 2,3.
In Brazil - since 2008 the world’s top consumer of 
agricultural pesticides -hazard-based cut-off criteria are 
adopted for pesticide registration. Only if active ingredients 
and other ingredients pass cut-off criteria for mutagenicity, 
carcinogenicity, teratogenicity, damage to reproductive 
organs and hormonal effects, are their risks subsequently 
assessed for risk management purposes, such as establishing an 
acceptable daily intake and imposing restrictions on use. The 
Brazilian hazard-based approach to pesticide registration is a 
unique example among the world’s most important regulatory 
scenarios. This article critically appraises potential usefulness 
and disadvantages of adopting such unique hazard-based cut-off 
criteria, and technical diffi culties in consistently applying them.
Legal and regulatory framework for pesticide 
registration in Brazil
According to Brazilian Pesticide Law (Federal Law No 
7.802, July 11th, 1989) “..pesticides, their ingredients and 
the like …shall only be manufactured, exported, imported, 
commercialized and used, if previously registered by a federal 
agency in accordance with the guidelines and requirements 
of health, environment and agriculture federal authorities”4. 
The law also establishes that (Art. 3rd § 6): “..it is forbidden to 
register pesticides, their ingredients and related products…” 
“b) for which there is no antidote or effective treatment in 
Brazil”, “c) that have teratogenic, carcinogenic or mutagenic 
properties revealed by updated results from experiments 
conducted by the scientifi c community”, “d) that produce 
hormonal disturbances and damage to reproductive organs, as 
demonstrated by updated procedures and experiments of the 
scientifi c community” 4.
The executive Decree No 4.074 (January 4th, 2002), which 
regulates the enforcement of Pesticide Law, additionally 
states (Art 31st) that “…studies on mutagenesis, carcinogenesis 
and teratogenesis, performed in at least two animal species, 
should be conducted in accordance with criteria accepted 
by recognized national or international technical-scientifi c 
institutions”, and also clarifi es what is to be considered a 
mutagenic compound: a substance “…able to induce mutations, 
noted in at least two tests, one to detect gene mutations, 
carried out also with the use of metabolic activation, and the 
other to detect chromosome mutations”5.
A regulation issued by Secretaria Nacional de Vigilância 
Sanitária do Ministério da Saúde (SNVS-MS - National 
Secretariat of Sanitary Surveillance of the Ministry of Health, 
i Paracelsus was a pseudonym adopted by Theophrastus Phillipus Auroleus Bombastus von Hohenheim (1493–1541), an irreverent Swiss-German physician who 
mocked at the ideas – shared by most of his contemporaries – on the treatment of illnesses based on statements made by Galen, Avicenna and other classic 
authors. The Paracelsus maxim cited in this article is found in one of his works: The Third Defense (“Die dritte Defension”).
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regulation no. 3, January 16th, 1992) provides additional 
information on what is to be considered a “carcinogenic” or 
a “teratogenic” substance, or yet a substance with “hormonal 
actions”, for putting into effect the Pesticide Law’s hazard-
based cut-off criteria6.ii The aforementioned health authority 
regulation states that:
“1.3.2 To evaluate the carcinogenicity of pesticides, 
criteria used by the International Agency for Research on 
Cancer (IARC) and the World Health Organization (WHO) 
will be adopted, and substances will be considered as 
carcinogenic if there is: a) scientifi c evidence based on 
valid epidemiological studies of human carcinogenicity, 
…. b) scientifi c evidence based on valid data of 
carcinogenicity in at least two laboratory animal 
species, showing increased incidences of malignant 
tumors : - of the same type at a determined body site 
or organ; - in different tests, preferably using different 
routes of administration and several doses; - at unusual 
degrees with reference to incidence, site, type of 
tumors, or age at which it appears. The evidence is 
strengthened if there is a direct relationship between 
number of animals bearing tumors and increase in 
dose. It should be understood as an unusual degree a 
statistically signifi cant difference compared to control 
group animals” 6.
“1.3.4 A pesticide is to be considered teratogenic 
when there is scientifi c evidence of teratogenesis based 
on valid data in humans or in studies (undertaken) 
with at least two laboratory animal species. Tests on 
teratogenicity should include a dose high enough to 
produce maternal toxicity and a low dose with no effect 
on the dam or on the offspring” 6.
“1.3.5 A pesticide is to be considered as having 
hormonal action which prevents it to be registered, 
when the no observed adverse effect level remains 
undetermined in experiments conducted with 
laboratory animals or in humans, (when) the hormonal 
change occurs at all tested doses and when the effect is 
not reversible upon discontinuation of administration, 
or exposure to the substance”6.
Endocrine disruption is one of the most controversial 
issues of modern toxicology and this topic and related 
matters, such as low dose effects and non-monotonic dose 
response curves, have been on the stage during the last two 
decades9. The starting point of this long and heated debate 
was the Wingspread Conference held in Racine, Wisconsin, 
USA, in 1991, during which the term endocrine disruptor was 
coined9. It is an astonishing fact that the cut-off criterion for 
“hormonal actions” was introduced by the Pesticide Law two 
years before the Wingspread conference. It is also amazing 
that health authority rules issued in January 19926 clearly 
stated that a substance would trigger the cut-off for hormonal 
action if the “no observed effect level remains undetermined 
in experiments”, which is consistent with the idea of “low dose 
effects”, one of today’s most controversial topics in toxicology.
Recently, the Brazilian regulatory agency (ANVISA) 
announced its plan to undertake an extensive revision of SNVS 
regulation no. 3, which was introduced nearly 20 years ago. 
Actually, a draft proposal of a new regulation is currently on the 
table for public comments10. According to this draft proposal, 
which has undergone a public consultation, hazard–based cut-
off criteria for pesticide approval for commercialization and 
use, particularly those regarding teratogenicity, mutagenicity 
and hormonal actions, would become far more restrictive.
On the cut-off criterion for teratogenicity, for instance, 
the draft proposal (Chapter III, Art 38) states: “A pesticide is 
to be considered teratogenic when there is scientifi c evidence 
of teratogenesis based on valid data in humans or in at least 
one laboratory animal species”10.
The new criterion for characterizing a pesticide compound 
as mutagenic (Art 39) is also more stringent: “A pesticide is 
to be considered mutagenic when there is scientifi c evidence 
(along this line) based on results from at least one in vivo 
study on the induction of chromosome aberrations”10. 
Therefore, in both cases (teratogenicity and mutagenicity) 
positive results of a test on a single animal species are 
considered to be suffi cient for preventing registration, 
without any additional comment on whether or not the mode 
of action in these cases is relevant to humans. It is noteworthy 
that, as far as the mutagenicity cut-off criterion is concerned, 
the new regulation proposed by ANVISA (in its Art. 39) comes 
into confl ict with the Government Decree No. 4.074 (Art. 31), 
a higher ranking law, which clearly states that a pesticide is 
to be considered as mutagenic when it is “..able to induce 
mutations, noted in at least two tests, one to detect 
gene mutations, carried out also with the use of metabolic 
activation, and the other to detect chromosome mutations”5.
Nonetheless, if the new rules proposed by ANVISA are put 
into effect, the most draconian cut-off criterion for pesticide 
registration will be that for substances suspected of having 
hormonal actions or causing injury to reproductive organs. 
According to article 41 of ANVISA’s draft proposal, “A pesticide 
is to be considered as causing hormonal disturbances and/or 
damage to reproductive system (organs) if the adverse effects, 
irrespective of being reversible or not upon discontinuation 
of substance administration or exposure, are demonstrated 
by valid data”10. Although the term “adverse effect” is used 
in the aforementioned statement, what is to be interpreted 
as “adversity” for characterizing an endocrine and/or 
reproductive hazard is not entirely clear. It should be noted that 
ii The Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA - National Agency for Health Surveillance), was established in 1999 (Law 9.782, 
January 26th, 1999)7. Until then, the Secretariat of Sanitary Surveillance – with far less resources and staff than today’s agency - was the Department of the 
Ministry of Health responsible for enforcing the Brazilian Health Surveillance Law (Law 6.360, September 23rd, 1976) at federal level. ANVISA’s duties include, but 
are not limited to, regulating and approving for sale: drugs, medical devices, food products, pesticides, tobacco, cosmetics and other consumer products8.
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transient changes of hormone levels are produced by stressors 
and by a number of stimuli and physiological conditions. They 
may result from adaptive (homeostatic) alterations of the 
organism and are not necessarily harmful. Moreover, “hormonal 
disturbances and/or damage to reproductive system” at times 
occur secondarily to other target organ effects, particularly 
if they give rise to severe systemic alterations. Since no 
reference is made to the context in which the “adverse effect” 
occurs (e.g., dose level and selectiveness towards endocrine/
reproductive systems), a plain and uncritical enforcement 
of the foregoing new regulation statement (Art. 41)10 may 
prevent registration of a number of pesticides the primary 
toxic targets of which are organs other than those of endocrine 
and/or reproductive systems.
Consequences of hazard taking precedence 
over risk in decision-making
Since the likelihood that a person will be harmed by a 
particular hazard depends upon exposure (and some other 
conditions), in principle, risk (probability) and not hazard 
(potential to harm) should be used for guiding public health 
interventions. A great contribution along this line was the 
systematization of the risk assessment process by the US 
National Academy of Sciences (NAS) in the early 1980s11. 
Therefore, when the Brazilian parliament passed the Pesticide 
Law in 19894, a systematized approach to risk assessment was 
already available and was being used worldwide to support 
regulatory decisions on chemicals. Although the word “risk” 
(“risco”) appears a couple of times in the law (e.g., “health 
and environmental risks”), it remains obscure whether it 
was used to refer to risk or hazard, a confusion that is often 
made by non-experts. At any rate, it is unclear why legislators 
ignored “risk assessment”, a systematic, scientifi cally-based, 
and more rational approach to decision-making than the 
adopted hazard-based cut-off criteria. 
It is more or less obvious that pesticides that pass the hazard-
based cut-off criteria established by the law may pose a higher 
health risk than those that failed to do it. A number of relevant 
health hazards are outside the set of hazards for which cut-off 
criteria were introduced. More importantly, however, is that, 
depending on the level of exposure, a slightly to moderately 
hazardous chemical may turn out to be a signifi cant health risk, 
and vice versa, i.e., a very hazardous substance may turn out to 
be a negligible risk to people’s health.
Some supporters of the current hazard-based cut-off 
criteria for pesticide registration have argued that this 
would never happen in Brazil because ANVISA subsequently 
undertakes a risk assessment for the substances that passed 
the initial cut-off criteria based purely on hazard. According to 
them, Brazil’s unique regulatory approach would in fact offer 
greater protection against harmful effects of pesticides on 
people’s health because, after excluding the substances that 
potentially cause some important adverse effects (regardless 
of their risks), exposure would be taken into account for 
risk management of the remaining ones. This is a misleading 
argument because it omits an important fact regarding our 
society’s dependence on the use of pesticides and how their 
market is regulated. Pesticides are needed for agriculture, 
to control insect-borne diseases, to exterminate domestic 
and urban pests, to protect wood from termites, and so on. 
If a particular pesticide is removed from the market (or not 
registered in the country) another product inevitably takes its 
place to fulfi ll existing agricultural or other needs. Therefore, a 
pre-selection based on hazard limits the number of substances 
available for a further selection based on risk and for choosing 
the best health risk management alternatives. Owing to this 
fact, a hazard-based selection, irrespective of whether it is 
followed by a risk assessment approach or not, is a bad option. 
To accomplish their mission to protect people’s health against 
harmful effects caused by pesticides, regulators have to keep 
one eye on the risk and the other on society’s need for a 
particular pesticide and alternatives.
Besides not consistently excluding the pesticide 
compounds that pose the highest health risks, hazard-based 
cut-off criteria are also diffi cult to implement. The Brazilian 
current regulations have a number of shortcomings that make 
implementation of hazard-based cut-off criteria even more 
diffi cult, error-prone and unpredictable.
Some additional shortcomings of Brazilian 
hazard-based cut-off criteria
No remark on the relevance of Mode of Action to humans. As 
far as human health is concerned, the extent to which animal 
data can be extrapolated to humans is a key question for using 
them to put into effect a hazard-based cut-off criterion for 
pesticide registration2. There are many examples of substances 
that are carcinogenic or teratogenic to laboratory rodents but 
not to humans due to species-specifi c modes of action. The 
artifi cial sweetener saccharin and d-limonene, a monoterpene 
found in a variety of plant essential oils (e.g. citrus peel oil), are 
examples of rat bladder and kidney carcinogens, respectively, 
that were shown not to cause cancer in humans12,13.
The chronic treatment of male rats with high doses of 
d-limonene produced an increased occurrence of tubular cell 
hyperplasia, adenomas and adenocarcinomas of the kidney12. 
Similar harmful effects were not observed in female rats or in 
male and female mice. Further investigations demonstrated 
that d-limonene1,2-oxide, a metabolite of d-limonene, binds to 
a protein (α2μ–globulin), leading to a progressive accumulation 
of “d-limonene1,2-oxide+α2μ–globulin” complex within the 
tubular cells (as hyaline droplets) that evolves to cause tubular 
cell death, which in turn stimulates a compensatory cell 
proliferation (restorative hyperplasia) that eventually results 
in renal tumors12. Since humans and mice (and female rats) do 
not synthesize appreciable amounts of α2μ–globulin or similar 
proteins, d-limonene nephropathy and renal cancers do not 
occur in these species (and gender)12.
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Some rodent studies, including a two-generation 
experiment in rats, showed that sodium saccharin caused 
a statistically signifi cant increase in bladder tumors in F1-
generation animals, a carcinogenic effect that was greater in 
males than in females13. It was also found that chronic treatment 
with sodium saccharin induced a hyperplastic response that 
apparently is needed for the development of epithelial bladder 
tumors in treated rats. Several nicely designed experiments 
by Samuel Cohen and coworkers indicated that hyperplasia 
was secondary to mild cytotoxicity in the superfi cial layers of 
the bladder epithelium. Injury to epithelial cells was caused 
by formation of a cytotoxic calcium-phosphate containing 
precipitate in the urine after administration of high doses of 
sodium saccharin13. A further long-term (beginning at birth and 
continuing throughout life) exposure of monkeys to saccharin 
found no indication of increased urothelial cells proliferation or 
tumors and no evidence of formation of a calcium phosphate-
containing urinary precipitate13. The difference between 
species was attributed to a much lower concentration (a 100 to 
1000-fold difference) of protein in the primate urine compared 
to the rat and mouse urine. Additionally, rat and mouse urine is 
much more concentrated than primate urine13.
In both cases, further mechanistic studies have clearly 
demonstrated that the mode of action by which d-limonene and 
saccharin caused cancer in rats does not occur in humans and 
non-human primates. There are a number of other examples 
of substances that produce carcinogenic effects in rodents by 
a mode of action that is unlikely to occur in humans. The other 
way around is also true. Owing to interspecies differences, 
a human carcinogen may remain undetected by studies 
conducted in laboratory rodents.
The uncertainty regarding possible interspecies 
differences also holds true for teratogenicity, mutagenicity 
and hormonal actions. Thalidomide, for instance, is a potent 
human (and non-human primate) teratogen, but causes no 
birth defects in rats and is only a weak teratogen in rabbits14. 
Phenobarbital and aspirin, to cite only two of many examples, 
are teratogenic to rats but apparently not to humans (both are 
among the medicines that are most often used by pregnant 
women; therefore, clinical information is available regarding 
human prenatal exposure).
At any rate, whenever feasible, kinetic similarities/
dissimilarities between test species and humans should be 
investigated to strengthen the predictive value of in vivo 
animal tests for teratogenicity, mutagenicity, carcinogenicity 
and hormonal actions.
The law, decree and current health authority rules on 
the hazard-based cut-off criteria make no comment on the 
relevance, to humans, of modes of action of adverse effects 
(cancer, birth defects/malformations, hormonal actions) in the 
test species. The new regulation proposed by ANVISA states 
that a pesticide is to be considered as carcinogenic if there is 
“..evidence (of carcinogenicity) in at least one experimental 
animal species, with a mode of action relevant to humans, or 
a mode of action not elucidated”10. Regarding teratogenicity, 
mutagenicity and hormonal actions, however, there is no word 
about the relevance, to humans, of the mode of action in the 
test species10. The proposed new regulation would greatly 
benefi t if a phrase such as “unless the mode of action in the 
laboratory animal species under consideration is demonstrated 
not to be relevant to humans” were introduced for all cases 
in which regulatory decisions are based on experimental data. 
Unsuitability of using teratogenicity as a 
cut-off criterion 
Another weakness of the Pesticide Law4 is that 
teratogenicity and not developmental toxicity was the 
outcome selected for application of a cut-off criterion. Although 
there have been inconsistencies in the use of the term, strictly 
speaking, “teratogenicity” refers to the ability to induce 
structural abnormalities (malformations) or dysmorphologies, 
also referred to as birth defects15. Teratogens, therefore, 
are biological (e.g., viruses, parasites, bacteria), chemical 
(e.g., drugs, environmental pollutants) or physical agents 
(e.g., radiation, hyperthermia) that cause malformations in 
developing embryos or fetuses. An increased occurrence of 
structural anomalies, however, is only one of several possible 
manifestations of adverse effects on prenatal development. In 
addition to a higher incidence of malformations, embryo and or 
fetus deaths, prenatal growth retardation (giving rise to “small 
for gestation age babies”) and functional disorders (some of 
which appear and are detected only after birth) may also occur 
as a result of mothers’ exposure to chemical, biological and 
physical agents during pregnancy. In summary, teratogenicity 
is a focus that is narrower than developmental toxicity and 
excludes a number of possible outcomes of chemical-induced 
harm to embryos and/or fetuses.
Furthermore, in rodent and rabbit fetuses at term, it is 
often diffi cult to distinguish malformations from (structure) 
deviations from the normal other than malformations (e.g., 
variations, retardations). The foregoing problem was addressed 
in a series of international workshops on harmonization 
of terminology and classifi catory terms in developmental 
toxicology that were held in Berlin, Germany between 1995 
and 201116,17. During the second Berlin workshop, a consensus 
was achieved to put forward a scheme of classifi cation for 
fetal abnormalities that consists of only two categories: 
“malformation and variation”, which were then defi ned as 
follows: 1) Malformation: “a permanent structural change 
that is likely to adversely affect the survival or health of the 
species under investigation”. 2) Variation: “a change that 
occurs within the normal population under investigation and 
is unlikely to adversely affect survival or health. This change 
might include a delay in growth or morphogenesis that has 
otherwise followed a normal pattern of development”16. In 
the subsequent fi ve workshops, discussions among experts 
from academia, regulatory agencies and industries focused 
on a number of fetal (structural) observations that did not fi t 
readily into one of the two categories (“grey zone anomalies”), 
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and for which there has been no consensus whether they are 
to be classifi ed as malformations or variations. The lack of 
agreement on the classifi cation of “grey zone anomalies” 
has been ascribed mainly to insuffi cient knowledge of their 
consequences for health and survival after birth17.
Since it has been agreed upon that teratogenicity is the 
ability to increase the incidence of malformations (but not 
the enhancement of variations only), occurrence of grey 
zone anomalies often leads to confl icting conclusions as to 
whether the substance is teratogenic (to the species under 
investigation) or not.
Another diffi culty in consistently applying a cut-off 
criterion to teratogenicity is the still standing controversy on 
the interpretation of fetal anomalies found only at maternally 
toxic dose levels. Some researchers think that increases in the 
occurrence of fetal anomalies, noted only at doses which are 
overtly toxic to the dams, are likely to be effects secondary to 
changes of maternal homeostasis and thus should not be taken as 
evidence of “developmental toxicity” or “teratogenicity”18,19. 
Other experts, including the author of this article, think that 
developmental toxicity is developmental toxicity irrespective 
of being maternally mediated or not18. At any rate, it is 
questionable to classify (label) a chemical as a teratogen 
(and developmental toxicant) if it increases the incidence of 
malformations (and or variations) only at unrealistically high 
doses (at which severe maternal toxicity is also noted).
Along this line, to avoid misinterpretations of results from 
developmental toxicity studies on environmental chemicals, 
Erminio Giavini and Elena Menegola have recently suggested 
that the upper limit of tested dose range should be “the 
maximum dose unable to produce maternal toxic effects 
extrapolated by previous short term toxicity studies”19. 
Guidelines for developmental toxicity studies generally require 
that the highest dose(s) should induce some signs of maternal 
toxicity. The OECD guideline 414 (Prenatal Developmental 
Toxicity Study), for instance, states that: “the highest dose 
should be chosen with the aim to induce some developmental 
and/or maternal toxicity (clinical signs or a decrease in 
body weight) but not death or severe suffering”20. Although 
Brazilian regulation (SVS No. 3, 1992) requires testing “…a 
dose high enough to produce maternal toxicity...”, it makes 
no recommendation on the upper limit of tested dose range 
based on severity of maternal toxic effects6.
Finally, it should be stressed that both controversial 
matters (i.e., to distinguish malformations from variations and 
the role of maternal toxicity) are less critical issues if a risk 
assessment rather than a hazard-based approach is adopted 
for decision-making on pesticide registration.
EU hazard-based criteria for labeling and 
registration of pesticides
As aforementioned, the Brazilian hazard-based cut-off 
criteria for pesticide registration are unique in the world. In 
the US, the Environmental Protection Agency (EPA) adopts a 
risk assessment approach to regulatory decision-making on 
pesticides. A hazard-based cut-off approach is employed for 
pesticide labeling and placing on the market in the EU21. 
There are, however, marked differences between the cut-off 
criteria that have been adopted in Brazil since 1989, and those 
introduced in the European Union in 2009. The differences 
between Brazilian and European Union cut-off criteria are 
summarized in Table 1.
The EU Directive 91/414, concerning the placing of plant 
protection products (pesticides) on the market, which entered 
into force on July 15th, 1991, stipulated that active substances 
contained in pesticide products must be assessed regarding 
possible risks for humans and animals22. More recently, the 
Plant Protection Products Regulation (EC) No. 1107/2009 
introduced a hazard-based approach to regulatory decisions21. 
According to this regulation, “An active substance, safener or 
synergist shall only be approved if … … it is not or has not 
to be classifi ed as …mutagen category 1A or 1B,..carcinogen 
category 1A or 1B …*, toxic for reproduction category 1A or 1B 
…*, ..is not considered to have endocrine disrupting properties 
that may cause adverse effects in humans …*;. …* unless ... 
exposure of humans is negligible”21.
The EU, therefore, has recently moved from using risk 
assessment to adopting hazard-based cut-off criteria to place 
pesticides on the market. Nonetheless, contrasting to Brazil, 
where cut-off criteria are based purely on health hazards, 
cut-off criteria adopted by the EU also take into account 
whether or not anticipated human exposures are negligible 
(unless ... exposure of humans is negligible). By a negligible 
exposure it is meant (Regulation (EC) 1107/2009) that “..the 
product would be used in closed systems or in other conditions 
excluding contact with humans and that residues of the 
active substance, safener or synergist concerned in food and 
feed do not exceed the default value set in accordance with 
point (b) of Article 18(1) of Regulation (EC) No 396/2005 
(European Council 2005), which is 0.01 mg/kg food”21. 
More pragmatic and better scientifi cally-based defi nitions 
of “negligible exposure” have also been suggested, such as 
using the concepts of margin of exposure (MOE) or threshold 
of toxicological concern (TTC)23,24,25.
It is of note that EU cut-off criteria take advantage of hazard 
categories described in the “Guidance on Classifi cation, 
Labelling and Packing (CLP) of substances and mixtures” 
(Regulation (EC) No 1272/2008),26 which are essentially the 
same of the United Nations’ “Globally Harmonised System of 
Classifi cation and Labeling of Chemicals” (GHS)27. CLP/GHS 
classifi cation scheme categories 1A (known) and 1B (presumed) 
are for known or presumed human mutagens, carcinogens, 
and reproductive toxicants26,27. Classifi cation into category 1A 
is largely based on evidence obtained directly from humans, 
while allocation to category 1B is based on data from animal 
studies. In both cases the strength of evidence is taken into 
account for classifi catory purposes. Chemicals for which there 
is “some” evidence are put into Category 2 (suspected human 
toxicant) while those chemicals that epidemiological studies 
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have proved to be not hazardous to humans, and those that 
have not been studied yet remain unclassifi ed26,27. It is of 
note that allocation to hazard category 2 does not prevent 
a pesticide from being placed on the market according to EU 
cut-off criteria21. The CLP/GHS classifi cation scheme also takes 
into consideration other facts depending on the particular 
hazard category. For instance, presumed human reproductive 
toxicants (category 1B) should exhibit “… clear evidence of 
an adverse effect….in the absence of other toxic effects,… or 
(that) adverse effect is considered not to be a secondary non-
specifi c consequence…”26,27. Moreover, relevance of mode of 
action to humans is also addressed (if “mechanistic information 
raises doubt about relevance for humans, classifi cation in 
Category 2 may be more appropriate.”)26,27.
Although still being basically a hazard-based cut-off 
approach, the EU decision-making process on pesticides 
incorporates elements of risk assessment, i.e., the idea that 
if exposure is very low (“negligible exposure”) the substance 
will pose no health risk. What is to be considered a “negligible 
exposure”, without previously assessing the risk of the 
substance under consideration, however, is a debatable topic 
and thus a weakness of the EU approach compared to the risk 
assessment process adopted by the US EPA.
At any rate, compared to the EU approach based on CLP/
GHS classifi cation (hazard categories 1A and 1B), the hazard-
based cut-off approach currently adopted in Brazil has plenty 
of defi ciencies and is a worse option if the goal is to put into 
effect regulatory decisions on pesticides aimed at protecting 
public health.
Concluding remarks
Hazard-based cut-off criteria do not take into account the 
“level of exposure”. Since the likelihood of being harmed by 
a chemical substance depends on exposure, approaches based 
only on hazard do not provide a rational basis for regulatory 
decisions. For guiding regulatory decisions on chemicals, health 
risk (probability to harm) should always take precedence over 
hazard (potential to harm).
Brazil adopts hazard-based cut-off criteria (mutagenicity, 
carcinogenicity, teratogenicity, hormonal actions) for pesticide 
registration4. Contrasting to the EU cut-off criteria for plant 
protection products that exempt “negligible” exposures21, 
the Brazilian cut-off criteria are based purely on hazard, 
i.e., they do not take exposure into account. Additionally, 
a number of shortcomings (e.g. no clear reference to the 
strength of evidence and to the relevance of the Mode of 
Table 1. Comparison of Brazilian current rules, and changes proposed by ANVISA (draft pproposal), with European Union rules for 
triggering hazard based cut-off criteria for placing pesticides on the market.
Brazilian rules European (EU) rules
Current rules (1992) Draft Proposal rules (2011)
Level of Exposure No mention to exposure No mention to exposure Not applicable if exposure of 
humans is negligible
Mode of action (MOA) (Ir)relevance of MOA to humans not 
considered
(Ir)relevance of MOA to humans not 
considered §
Not applicable if MOA is shown not 
to be relevant to humans 
Mutagenicity Positive in at least two tests, 
gene mutation in vitro and in vivo 
clastogenicity 
Positive in at least one in vivo 
test for induction of chromosome 
aberrations
CLP/GHS categories 1A (known) or 
1B (presumed) human mutagen 
Carcinogenicity Evidence in humans and or positive 
in at least two species, dose-
effect relationship strenghtens the 
evidence
Evidence in humans and or in 
at least 2 species, and or in at 
least one species with a MOA 
either relevant to humans or not 
elucidated yet. §
CLP/GHS categories 1A (known) or 
1B (presumed) human carcinogen
Teratogenicity Evidence in humans or positive in at 
least two species. The highest dose 
tested should be maternally toxic. 
No comment on the interpretation 
of fetal malformations found only in 
the presence of maternal toxicity. 
Evidence in humans or positive in 
at least one species
No specifi c cut-off criterion 
Toxicity to reproduction No cut-off criterion No cut-off criterion CLP/GHS categories 1A (known) or 
1B (presumed) human reproductive 
toxicant
Hormonal actions or endocrine 
disrupting effects
Applicable only to irreversible 
hormonal changes (all tested 
doses) and if NOAEL remains 
undetermined
Applicable also to reversible 
hormonal changes; what is to be 
considered an adverse effect is 
unclear
Applicable if pesticide has 
endocrine disrupting properties 
that may cause adverse effects in 
humans
§ Only for carcinogenicity draft proposal rules make a remark on the relevance of the MOA to humans. The rule, however, is not entirely clear. As 
written (in Portuguese) the reader may misinterpret that a positive result in two animal species would trigger the cut-off for carcinogenicity even if, 
for both species, the MOA is shown not to be relevant to humans. The text should be rephrased to make it clearer that cut-off shall not be triggered 
if MOA is demonstrated not to be relevant to humans. 
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Action to humans) of the Pesticide Law and health authority 
regulations make the Brazilian cut-off criteria diffi cult to be 
consistently implemented. A draft proposal of a new regulation 
on pesticides has been recently published by ANVISA and is on 
the table to receive criticisms and comments10. As a rule, the 
proposed changes are not based on sound toxicological science 
principles and make implementation of cut-off criteria far 
more restrictive. This particularly holds true for proposed new 
rules to put into effect cut-off criteria for teratogenicity and 
hormonal actions. According to the draft proposal, “evidence 
of teratogenesis in at least one laboratory animal” would 
trigger the cut-off criterion10. No remark is made, however, on 
exemption if the mode of action is shown not to be relevant to 
humans. The proposed rules for triggering a cut-off criterion 
for hormonal actions are even more drastic. ANVISA proposes 
that any hormonal disturbance, irrespective of being reversible 
or irreversible upon treatment discontinuation, would trigger 
the cut-off criterion for hormonal action10. Again no remark is 
made on relevance to humans. It also remains unclear what is 
to be considered an adverse effect resulting from a reversible 
hormonal disturbance.
Brazil has become the world’s largest consumer of 
agricultural pesticides and there has been growing concern 
about the adverse health consequences of uncontrolled and 
careless use of such products in some rural areas. The time has 
come to move from cut-off criteria based purely on hazard to 
risk assessment, which is a more rational, reliable, fl awless, 
and effective approach to health risk management purposes. 
Any amendment to a Federal law (Pesticide Law), however, 
has to be discussed and approved by the parliament before 
being enforced. A cut-off approach based primarily on hazard 
but also incorporating “negligible exposure” as an exemption 
- as adopted by EU - is an alternative that does not require 
changing the Pesticide Law. It can be put into effect by a lower 
ranking regulation issued by the health authority (ANVISA). 
Along this line, Brazil would also greatly benefi t from taking 
advantage of GHS hazard categories 1A and 1B27 as cut-off 
criteria for mutagenicity and carcinogenicity. The potential 
to induce malformations (“teratogenicity”) is part of a more 
comprehensive GHS category (“toxicity for reproduction”) 
and thus it is needed to redefi ne 1A and 1B categories for this 
particular hazard-based cut-off criterion. As far as hormonal 
actions are concerned, however, the current rules (SNVS 
regulation No. 3, January 16th, 1992)6 make more sense than 
those proposed by ANVISA in January 201110. According to the 
current rules, a cut-off for hormonal actions is triggered if 
“no observed adverse effect levels remains undetermined” 
and “the effect is not reversible” upon discontinuation of 
exposure, whereas the proposed new rules do not make an 
exception to the existence of an experimentally determined 
NOAEL (no observed adverse effect level) and triggers the 
cut-off even if hormonal changes are reversible. Reversible 
hormonal alterations are not necessarily harmful and 
experimentally derived NOAELs are reliable tools that can be 
used by regulators to manage health risks. As reminds us one 
of the most fundamental concepts of the modern science of 
toxicology, foreseen by Paracelsus nearly 500 years ago, the 
dose (exposure) “makes a substance not a poison”.
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